Shenzhen Rivaroxaban Co.,Ltd
Home
About us
Products
Rivaroxaban
Pharmaceutical Intermediates
Tegprazan
VeMurafenib
Anti-diabetic
Antiviral Drug
Antidepressants
Anti-cancer Drugs
High Polymer Materials
Complementary Medicines
Cardiovascular Medications
News
Blog
Contact us
Language
English
Home
>
Blog
LATEST NEWS
Statement
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID
Curcumin and liver injury risk correlation does not imply causation
Antimalarial drug discovery: progress and approaches
Apellis Axing 25% of Staff, Shifting Resources to GA Drug
Jun 01, 2023
Statement
read more
May 31, 2023
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID
read more
May 30, 2023
Curcumin and liver injury risk correlation does not imply causation
read more
May 29, 2023
Antimalarial drug discovery: progress and approaches
read more
May 28, 2023
Apellis Axing 25% of Staff, Shifting Resources to GA Drug
read more
May 27, 2023
RACGP
read more
May 26, 2023
Ayush Clinic inaugurated at NIMS Hospital in Telangana. Here's why doctors are opposing it
read more
first
6
7
8
9
last